In a significant stride toward strengthening the UAE’s global footprint in healthcare and life sciences, Mubadala Investment Company has unveiled its newest venture Mubadala Bio, a dedicated pharmaceuticals company designed to reinforce national drug security and elevate the Emirates’ manufacturing capabilities. With an impressive production capacity of over 2.5 billion tablets and capsules and 120 million units of intravenous solutions and injectables, Mubadala Bio positions the UAE as a formidable player in the international pharmaceutical market. Operating from 10 cutting-edge facilities spread across the Middle East, Africa, Asia, and Europe including six strategically located within the UAE the company is set to serve more than 100 countries, anchoring Abu Dhabi as a central hub in the global health ecosystem.
Speaking on the launch, Dr. Bakheet Al Katheeri, CEO of Mubadala’s UAE Investments Platform, emphasized the transformative impact of this initiative, stating that Mubadala Bio is not just a business venture, but a strategic leap toward fostering innovation, economic resilience, and long-term growth within the life sciences sector. The announcement was made during the Make It In The Emirates summit, a pivotal platform focused on showcasing the UAE’s industrial progress and ambition.
The launch of Mubadala Bio aligns with a series of bold investments made by the company in recent months, reinforcing its commitment to the healthcare and life sciences industries. From acquiring majority stakes in local and global pharmaceutical distributors to partnering with international firms to grow its R&D and manufacturing footprint, Mubadala is intentionally shaping a future ready, innovation-driven health infrastructure. With assets under management reaching Dh1.2 trillion ($326 billion) in 2024 and a remarkable 10.1% annualized return over the last five years, Mubadala is not only investing in sectors of strategic importance such as AI, healthcare, and advanced manufacturing but also driving the narrative of what a forward-looking sovereign investment model looks like.
With Mubadala Bio, the UAE takes a defining step toward becoming a global life sciences leader, proving that visionary policy, backed by strategic investment, can turn national ambition into international impact.
